These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17962822)

  • 1. Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra).
    Lin HC; Lu PL; Chang CH
    Eye (Lond); 2007 Dec; 21(12):1540-1. PubMed ID: 17962822
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.
    Khachi H; O'Connell R; Ladenheim D; Orkin C
    J Antimicrob Chemother; 2009 Oct; 64(4):871-3. PubMed ID: 19628472
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis.
    Skolik S; Willermain F; Caspers LE
    Ocul Immunol Inflamm; 2005 Dec; 13(6):483-5. PubMed ID: 16321897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
    Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved tolerability and quality of life with the new lopinavir/ritonavir tablet formulation.
    Olmo M; Ferrer E; Curto J; Barragán P; Saumoy M; Perulero N; Podzamczer D
    J Infect; 2008 Dec; 57(6):503-5. PubMed ID: 18952298
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir.
    Ghosn J; Duvivier C; Tubiana R; Katlama C; Caumes E
    Clin Infect Dis; 2005 Nov; 41(9):1360-1. PubMed ID: 16206117
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between lopinavir/ritonavir and warfarin.
    Hughes CA; Freitas A; Miedzinski LJ
    CMAJ; 2007 Aug; 177(4):357-9. PubMed ID: 17698824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.
    Chaubey SK; Sinha AK; Phillips E; Russell DB; Falhammar H
    Sex Health; 2009 Sep; 6(3):254-7. PubMed ID: 19653965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
    la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
    Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
    AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rifabutin-associated hypopyon uveitis in patient with acquired immunodeficiency syndrome].
    Ishiguchi N; Ueno K; Yanagihara M; Kadono K; Oshika T
    Nippon Ganka Gakkai Zasshi; 2010 Aug; 114(8):683-6. PubMed ID: 20803988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Uvéites médicamenteuses - Panuvéite sur RifabutinDrug-induced uveitis - panuveitis with Rifabutin].
    Beknazar E; Viet Tran H; Andrei SM; Martinez A; Vaudaux J; Guex-Crosier Y
    Klin Monbl Augenheilkd; 2011 Apr; 228(4):374-5. PubMed ID: 21484657
    [No Abstract]   [Full Text] [Related]  

  • 17. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between ritonavir and levothyroxine.
    Tseng A; Fletcher D
    AIDS; 1998 Nov; 12(16):2235-6. PubMed ID: 9833871
    [No Abstract]   [Full Text] [Related]  

  • 19. Nifedipine-lopinavir/ritonavir severe interaction: a case report.
    Baeza MT; Merino E; Boix V; Climent E
    AIDS; 2007 Jan; 21(1):119-20. PubMed ID: 17148983
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.